Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 16/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659837 | 0.75 | ADORA2A (0.59) | ADORA1ADORA2A | |
| SCHEMBL1332972 | 0.73 | ADORA1 (0.52) | ADORA1ADORA2A | |
| SCHEMBL29082599 | 0.71 | NUDT1 (0.41) | KMT2A | |
| SCHEMBL24309649 | 0.71 | ADORA1 (0.63) | ADORA1ADORA2ALMNA | |
| SCHEMBL4900909 | 0.71 | ADORA1 (0.40) | ADORA1ADORA2ALMNA | |
| SCHEMBL14127720 | 0.70 | ADORA1 (0.61) | ADORA1ADORA2ALMNAGFERKMT2A | |
| SCHEMBL4904056 | 0.69 | ADORA1 (0.39) | ADORA1ADORA2ALMNA | |
| SCHEMBL4582424 | 0.69 | ADORA1 (0.83) | ADORA1ADORA2AGFERKMT2A | |
| SCHEMBL13377688 | 0.67 | ADORA1 (0.57) | ADORA1ADORA2ALMNAGFERKMT2A | |
| SCHEMBL508845 | 0.67 | ADORA1 (0.57) | ADORA1ADORA2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513242-B2 | Pyrimidine compounds and methods of making and using same | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CYSTIC FIBROSIS FOUNDATION | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CFTR, GPR17, TYMS | ADORA1 122/4885ADORA2A 158/4885LMNA 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.